The Motley Fool··Josh Kohn-LindquistBoston Scientific Tumbles 9% on Lukewarm Watchman Trial Despite Meeting All Endpoints
Boston Scientific shares fell 9% after Watchman FLX trial met all endpoints but disappointed investors seeking transformative clinical data to accelerate growth.
SYKMDTBSXstock declineclinical trial